News and Trends 17 May 2023
Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases
Scribe Therapeutics Inc., a company creating genetic medicines through its CRISPR by Design approach to genetic modification, has announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The deal gives Prevail exclusive rights to Scribe Therapeutics’ CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed […]